Effects of the sibutramine therapy on pulmonary artery pressure in obese patients

Basit Öğe Kaydı
dc.authorwosidKoksal, Nurhan/AAA-3249-2022
dc.authorwosidGüven, Aytekin/AAJ-8546-2021
dc.authorwosidKöksal, Nurhan/AAG-5849-2021
dc.contributor.authorGuven, A
dc.contributor.authorKoksal, N
dc.contributor.authorCetinkaya, A
dc.contributor.authorSokmen, G
dc.contributor.authorOzdemir, R
dc.date.accessioned2024-08-04T20:13:37Z
dc.date.available2024-08-04T20:13:37Z
dc.date.issued2004
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAim: Obesity is a major global public health problem. Previous drugs (dexfenfluramine and fenfluramine) used for the treatment of obesity have been withdrawn due to various cardiac side effects. Sibutramine is an anti-obesity agent. The purpose of this study was to assess cardiac valve disease and pulmonary artery pressure (PAP) of the patients who used once daily doses of sibutramine. Methods: One hundred and six obese patients (51 men and 55 women) determined to have minimal tricuspid regurgitation (TR) on echocardiographic examination were included in the study. All patients had a complete physical examination, complete blood count and measurement of lipid parameters, and echocardiography was performed by which cardiac valves and PAP were evaluated. After the mean duration of 24-week of follow up, all examinations were repeated for each patient. Results: The drug was well tolerated by all patients for the follow-up period. A significant weight loss was recorded in all patients compared to the baseline values (93.1 +/- 9.6 kg vs. 85.8 +/- 7.7 kg, p < 0.001). Blood pressures and heart rate of the patients increased compared to the baseline measurements (systolic 122.3 +/- 8.5 vs. 124 +/- 10.2 mmHg, p = 0.128, diastolic 79.3 +/- 4.7 vs. 80 +/- 5.7 mmHg, p = 0.42 and heart rate 79.5 +/- 6.5 vs. 85 +/- 5.7 beats/min, p < 0.001). Echocardiographically determined aortic or mitral valve dysfunction appeared in none of the patients. PAP lightly increased after the treatment but the difference between pre and post-treatment values was not found statistically significant (14.7 +/- 1.8 vs. 16.3 +/- 1.6 mmHg, p = 0.06). Conclusions: A 24-week treatment with sibutramine does not affect heart valves and pulmonary artery pressure.en_US
dc.identifier.doi10.1111/j.1463-1326.2004.00314.x
dc.identifier.endpage55en_US
dc.identifier.issn1462-8902
dc.identifier.issue1en_US
dc.identifier.pmid14686963en_US
dc.identifier.scopus2-s2.0-0742306737en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage50en_US
dc.identifier.urihttps://doi.org/10.1111/j.1463-1326.2004.00314.x
dc.identifier.urihttps://hdl.handle.net/11616/93737
dc.identifier.volume6en_US
dc.identifier.wosWOS:000187255700008en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBlackwell Publishing Ltden_US
dc.relation.ispartofDiabetes Obesity & Metabolismen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectechocardiographyen_US
dc.subjectheart valvesen_US
dc.subjectpulmonary artery pressureen_US
dc.subjectsibutramineen_US
dc.titleEffects of the sibutramine therapy on pulmonary artery pressure in obese patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu